Goldman Sachs Group Inc. acquired a new stake in shares of Myovant Sciences Ltd. (NYSE:MYOV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,853 shares of the company’s stock, valued at approximately $174,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Voya Investment Management LLC increased its stake in shares of Myovant Sciences by 5.4% during the 2nd quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock valued at $4,931,000 after acquiring an additional 21,478 shares during the last quarter. OxFORD Asset Management LLP increased its stake in shares of Myovant Sciences by 15.4% during the 2nd quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after acquiring an additional 3,971 shares during the last quarter. BB Biotech AG increased its stake in shares of Myovant Sciences by 0.4% during the 2nd quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock valued at $38,811,000 after acquiring an additional 14,336 shares during the last quarter. Emory University acquired a new position in shares of Myovant Sciences during the 2nd quarter valued at about $1,512,000. Finally, Swiss National Bank acquired a new position in shares of Myovant Sciences during the 2nd quarter valued at about $294,000. 79.84% of the stock is owned by institutional investors.

Shares of Myovant Sciences Ltd. (NYSE MYOV) opened at $12.97 on Wednesday. Myovant Sciences Ltd. has a 1 year low of $9.92 and a 1 year high of $18.85.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/14853-shares-in-myovant-sciences-ltd-myov-purchased-by-goldman-sachs-group-inc/1719109.html.

MYOV has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a research note on Friday, November 10th. Evercore ISI initiated coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating for the company. JMP Securities reaffirmed an “outperform” rating and set a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a research note on Wednesday, October 4th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $22.50.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd. (NYSE:MYOV).

Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.